Herceptin
Trovati 29 articoli
- Breast cancer: change in HER2 status after treatment with Trastuzumab
- Researchers at The University of Texas MD Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. However, of those women who had residual disease, about one-th... (Leggi Articolo)
- Breast cancer: dose-dense chemotherapy linked to lower cardiac effects
- A new pilot study by Researchers at Memorial Sloan-Kettering Cancer Center ( MSKCC ) found that breast cancer patients can be treated safely with a dose-dense regimen of standard chemotherapy agents and the antibody Trastuzumab ( Herceptin ), a drug that has previously been shown to cause cardiac... (Leggi Articolo)
- Tykerb blocks the growth of breast cancer cells that spread to the brain in a mouse model
- Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the growth of breast cancer cells that migrate to the brain. The small molecule used in the studies was... (Leggi Articolo)
- Advanced breast tumor: FDA has approved Tykerb
- The FDA ( Food and Drug Administration ) has approved Tykerb ( Lapatinib ), a new targeted anti-cancer treatment, to be used in combination with Capectabine ( Xeloda ), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive. The combination treatment is ... (Leggi Articolo)
- Lapatinib in brain metastases associated with breast cancer
- One-third of women with HER2-positive metastatic breast cancer currently develop brain metastases. Once the disease advances to this stage, overall disease prognosis is poor with the average one-year survival from diagnosis estimated at about 20 percent. Results from an ongoing, multicenter ... (Leggi Articolo)
- Advanced breast cancer: Neuvenge, an active cellular immunotherapy
- Dendreon announced publication of results from a Phase 1 study of Neuvenge, an investigational active cellular immunotherapy, in the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of Neuvenge in women with HER2/neu-positive breast ... (Leggi Articolo)
- Lapatinib in combination with Paclitaxel as first-line treatment for patients with metastatic or relapsed advanced breast cancer
- Paclitaxel ( Taxol ) is one of the most commonly used chemotherapies in breast cancer. Therefore, the evaluation of Lapatinib ( Tykerb ) in combination with this treatment is of high importance. A large, randomized, multicenter, prospective trial evaluated a total of 580 patients either negat... (Leggi Articolo)
- Lack of response to Herceptin may be reversed with addition of a PI3K inhibitor
- Breast cancer patients with HER2-positive tumors who don't respond to Herceptin ( Trastuzumab ) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, say researchers at The University of Texas M. D. Anderson Cancer Center. The findings were m... (Leggi Articolo)
- Europe: Herceptin for early-stage in HER2-positive breast cancer
- The European Commission has approved Herceptin ( Trastuzumab ) for patients with early-stage HER2-positive breast cancer following surgery and standard chemotherapy. The approval is based on impressive results from the international HERA ( HERceptin Adjuvant ) study which showed Herceptin fo... (Leggi Articolo)
- Advanced HER2-positive breast cancer: Herceptin added to hormonal therapy prolongs progression-free survival
- Data from TAnDEM study have shown that the addition of Trastuzumab ( Herceptin ) to the hormonal therapy, Anastrozole ( Arimidex ), improves progression-free survival for patients whose advanced breast cancer is hormone receptor-positive, as well as HER2-positive. Hormone receptor-positive br... (Leggi Articolo)
- CDK4 as a targeted approach to treating aggressive breast cancers
- Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment. A team led by Qunyan Yu, and Peter Sicinski, of Dana-Farber r... (Leggi Articolo)
- Early breast tumor: NICE recommends Trastuzumab
- NICE has recommended Herceptin ( Trastuzumab ) for women with early stage HER2-positive breast cancer, except where there are concerns about the woman’s cardiac function. The recommendations are as follows: 1.1 Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence ( ... (Leggi Articolo)
- Interleukin-12 may help antibody-based drugs fight cancer
- A study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system. This study is the first to indicate that the drug Trastuzumab, also known as Herceptin, may work better when it is followed by injections of interleuk... (Leggi Articolo)
- AlphaB-crystallin protein linked to aggressive breast cancer
- A study led by Northwestern University researchers has demonstrated that a protein called alphaB-crystallin, which normally protects cells from stress damage, triggers events that may cause breast cancer when overactive. Breast cancer is the most common cancer in women and is responsible for ... (Leggi Articolo)
- p95HER-2 helps predict breast cancer outcome
- Researchers at Oregon Health & Science University Cancer Institute have identified a protein fragment in some human breast cancers that may help predict a chances of survival. The presence of the fragment, called p95HER-2, in breast cancer tissue correlates closely with lymph node metastasis ... (Leggi Articolo)
- p95HER-2 helps predict breast cancer outcome
- Researchers at Oregon Health & Science University Cancer Institute have identified a protein fragment in some human breast cancers that may help predict a chances of survival. The presence of the fragment, called p95HER-2, in breast cancer tissue correlates closely with lymph node metastasis ... (Leggi Articolo)
- p95HER-2 helps predict breast cancer outcome
- Researchers at Oregon Health & Science University Cancer Institute have identified a protein fragment in some human breast cancers that may help predict a chances of survival. The presence of the fragment, called p95HER-2, in breast cancer tissue correlates closely with lymph node metastasis ... (Leggi Articolo)
- Advanced breast cancer: Tykerb an alternative to Herceptin
- A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks with Capecitabine alone, p=0.00032 ) in women with refractory advanced or metastatic ErbB2 positive ... (Leggi Articolo)
- Advanced breast cancer: Tykerb an alternative to Herceptin
- A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks with Capecitabine alone, p=0.00032 ) in women with refractory advanced or metastatic ErbB2 positive ... (Leggi Articolo)
- HER-2 positive breast cancer: Herceptin added to radiation therapy
- Researchers in the North Central Cancer Treatment Group ( NCCTG ) have shown that patients who receive Trastuzumab ( Herceptin ) at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do ... (Leggi Articolo)
- Early-stage breast carcinoma: chemotherapy plus Trastuzumab
- A joint interim analysis of two studies of Trastuzumab ( Herceptin ) in early-stage breast cancer showed that HER2-positive breast cancer patients receiving Herceptin plus chemotherapy had a 52 percent reduction in the risk of disease recurrence compared to those patients who received chemothera... (Leggi Articolo)
- Trastuzumab improves survival in early breast cancer
- Two Phase III trials of Herceptin ( Trastuzumab), a monoclonal antibody, were stopped early after a preliminary joint interim analysis demonstrated an improvement in disease-free survival and in overall survival. The trials compared Herceptin plus chemotherapy to chemotherapy alone as adjuvan... (Leggi Articolo)
- Herceptin plus chemotherapy improves disease-free survival in early breast cancer
- The therapy Herceptin with chemotherapy in patients with early stage breast cancer significantly increases disease-free survival time in women who test positive for a genetic mutation. The study also tested Herceptin with a chemotherapy combination that eliminated Adriamycin, an anthracycline ... (Leggi Articolo)
- Early-stage breast cancer, Herceptin after adjuvant chemotherapy improves disease-free survival
- Herceptin ( Trastuzumab ), a recombinant monoclonal antibody against HER2, previously shown to prolong survival in advanced breast cancer, reduced the recurrences in patients with early-stage disease when given for one year following standard chemotherapy. These are the encouraging findings in... (Leggi Articolo)
- Herceptin plus chemotherapy reduces risk of recurrence in early-stage HER2-positive breast cancer
- A large phase III trial in early-stage HER2-positive breast cancer has shown that adding Herceptin ( Trastuzumab ) to chemotherapy significantly reduces the risk of disease recurrence compared to chemotherapy alone. This study follows three earlier phase III studies which also confirmed Herc... (Leggi Articolo)
- Can healthcare systems afford Herceptin for early breast cancer ?
- A research into the cost of using the breast cancer drug Herceptin ( Trastuzumab ) warns that healthcare authorities and the organisations advising them should not rush to prescribe it for early breast cancer without working out extremely carefully the budget implications and cost-effectiveness o... (Leggi Articolo)
- Herceptin plus adjuvant chemotherapy improves outcomes among women with surgically removed HER2-positive breast cancer
- Researchers have presented the combined results of two trials that compared adjuvant chemotherapy with or without concurrent Herceptin ( Trastuzumab ) in women with surgically removed HER2-positive breast cancer. The studies showed Herceptin therapy to be highly superior to standard treatment,... (Leggi Articolo)
- Gamma-linolenic acid inhibits action of Her-2/neu, responsible for some breast cancers
- Gamma-linolenic acid ( GLA ), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 percent of all breast cancers. " Breast cancer patients with Her-2/neu-positive tumors have an a... (Leggi Articolo)
- Metastatic breast carcinoma: Paclitaxel and Bevacizumab in first-line
- A study of Bevacizumab ( Avastin ) plus Paclitaxel chemotherapy in first-line metastatic breast cancer met its primary efficacy endpoint of improving progression-free survival, compared to chemotherapy alone. Results from an interim analysis of this study showed that patients receiving Bevac... (Leggi Articolo)
